Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment, today debuts its popular MelApp mobile app for Android™ devices. Now, health-conscious consumers can easily learn about melanoma and identify areas on their skin which may need attention from a specialist, anytime, anywhere with their iPhone, iPod Touch and iPad, as well as Android smartphone. First launched this summer for iPhone, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the smartphone’s GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical diagnosis and treatment. “Being currently used in nearly 50 countries, and having been named one of the ‘Top 10 Apps That Could Save Your Life’ in a recent issue of Parade Magazine, MelApp has become a worldwide success,” stated Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation. “With the launch of MelApp for Android our goal was to extend the availability of this easy to use, inexpensive and potentially life-saving app to the more than 46 percent of the smart phone market that use Android devices, according to Nielsen.” Now available for iPhone, iPod touch, and iPad, as well as for Android, MelApp is available for download at a special limited time price of $1.99 at the following app marketplaces:
- iTunes App Store - http://itunes.apple.com/us/app/melapp/id446669257?mt=8&ls=1
- Android Marketplace - https://market.android.com/search?q=MelApp&c=apps
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.